rfpseek Federal opportunities
Menu
Active Bid Combined Synopsis/Solicitation

NOI - A Non-Invasive Prognostic Biomarker - Circul

Solicitation 75N98027Q00007 Notice 66af16818b144456af1ddc0d52fc9378

The agency is asking for bids, quotes, or proposals. Check the notice for instructions and the deadline.

No confirmed award in the records available to us. That does not establish that bidding is still open. Award records can lag.

Sign in to get updates for this solicitation.

Open official notice on SAM.gov
PostedOct 13, 2026
Response deadlineOct 23, 2026 1:00 PM UTC
DepartmentHEALTH AND HUMAN SERVICES, DEPARTMENT OF
Set-aside Unrestricted Unrestricted. No set-aside.
Posted Oct 13, 2026; due Oct 23, 2026. That is 10 days to respond.

Scope

Opportunity description

(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith the format in FAR Subpart 12.6, as supplemented with additional information includedin this notice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00007.

This solicitation is issued as a Notice ofIntent (NOI) for a non-competitive combined synopsis/solicitation to award a contract orpurchase order without providing for full and open competition (including brand-name, ifapplicable).

This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold.

Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to University of Alabama at Birmingham, 701 S 20th Street, Birmingham, AL 35294-0001-0001, for research support to develop and validate circulating cell-free DNA (cfDNA) as a blood-based biomarker of chlorine-induced acute lung injury, using the Matalon Laboratory's sole-source validated murine chlorine inhalation injury model, established mechanistic expertise, access to its actively enrolling aspiration pneumonitis biorepository (human proxy cohort), existing collaborative infrastructure with the NHLBI Laboratory of Precision Omics, and continuity with peer-reviewed federal funding (NIH R01 HL031197).

These capabilities are not available from any other source and are essential to the project's feasibility. (iii)The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv)The associated NAICS code is 541380, Testing Laboratories and Services, and the small business size standard is $19.0 million.

This requirement is not set aside for small business.

FAR references

These Federal Acquisition Regulation references appear in the notice description.

Links open the current FAR text on Acquisition.gov. Check the full solicitation on SAM.gov for clause dates, alternates, deviations, and additional clauses in attachments.